Article

Sclera 'driving the bus' as far as ONH biomechanics

"Why do some people develop glaucoma and some do not even at the same level of IOP?" J. Crawford Downs, PhD, asked rhetorically in a talk about the biomechanics of the optic nerve head (ONH) as part of a symposium about ocular biomechanics. "We think it's perhaps due to differences in anatomy and geometry, tissue composition, ocular blood flow, and cellular reactivity."

"Why do some people develop glaucoma and some do not even at the same level of IOP?" J. Crawford Downs, PhD, asked rhetorically in a talk about the biomechanics of the optic nerve head (ONH) as part of a symposium about ocular biomechanics. "We think it's perhaps due to differences in anatomy and geometry, tissue composition, ocular blood flow, and cellular reactivity."

Dr. Downs, associate scientist and director of the ocular biomechanics laboratory at the Devers Eye Institute, Portland, OR, added, "Glaucoma is a very complicated, multifactorial disease, and certainly, it is driven by IOP, but there are a lot of other extraocular determinants as well as other factors involved."

He defined ONH biomechanics as the interactions between IOP and connective tissue structural stiffness in the ONH and surrounding sclera.

"The sclera is kind of 'driving the bus' as far as ONH biomechanics," Dr. Downs said.Describing what researchers currently know about ONH biomechanics, he said, "Scleral and ONH biomechanics vary tremendously among individuals. This work is still in its infancy.

"Scleral and ONH biomechanics are involved in the development and progression of glaucoma through a variety of mechanisms . . . and likely play a principle role in an individual's susceptibility to IOP," he said. "Scleral mechanics actually drive macro-scale ONH mechanics to a large degree, and at the beam level, laminar mechanics are very complex."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.